Abstract
Background:Special AT-rich sequence-binding protein 2 (SATB2) is a novel diagnostic marker of colorectal cancer (CRC), and loss of SATB2 has been linked to poor survival from the disease. In this study, we validated the prognostic ability of SATB2 expression in a large, prospective CRC cohort.Methods:Immunohistochemical SATB2 expression was assessed in 527 incident CRC cases from the Malmö Diet and Cancer Study. Kaplan–Meier analysis and Cox proportional hazards modelling were used to explore the impact of SATB2 expression on cancer-specific survival (CSS) and overall survival (OS).Results:High SATB2 expression was associated with a prolonged CSS in the full cohort (hazard ratio (HR)=0.61; 95% CI 0.41–0.92) and in colon cancer (HR=0.39; 95% CI 0.20–0.75), remaining significant in multivariable analysis of colon cancer (HR=0.49; 95% CI 0.25–0.96), with similar findings for OS. In curatively resected stage III-IV patients, a significant benefit from adjuvant and/or neoadjuvant therapy was observed for SATB2 high tumours (Pinteraction=0.037 for OS) and high SATB2 expression in rectal cancer correlated with an enhanced effect of neoadjuvant therapy (Pinteraction=0.033 for OS).Conclusion:High SATB2 expression is an independent marker of good prognosis in colon cancer and may modulate sensitivity to chemotherapy and radiation.
Highlights
Special AT-rich sequence-binding protein 2 (SATB2) is a novel diagnostic marker of colorectal cancer (CRC), and loss of SATB2 has been linked to poor survival from the disease
SATB2 expression was lower in colon cancer with 101 out of 321 (31.5%) negative tumours compared with rectal cancer, where 46 out of 193 (23.8%) tumours were SATB2 negative, this difference did not reach statistical significance (R 1⁄4 0.081, P 1⁄4 0.066)
This study was conducted to examine the prognostic impact of SATB2 expression in incident Colorectal cancer (CRC) cases from a large prospective, population-based cohort study
Summary
Special AT-rich sequence-binding protein 2 (SATB2) is a novel diagnostic marker of colorectal cancer (CRC), and loss of SATB2 has been linked to poor survival from the disease. We validated the prognostic ability of SATB2 expression in a large, prospective CRC cohort. METHODS: Immunohistochemical SATB2 expression was assessed in 527 incident CRC cases from the Malmo Diet and Cancer Study. Kaplan – Meier analysis and Cox proportional hazards modelling were used to explore the impact of SATB2 expression on cancerspecific survival (CSS) and overall survival (OS). RESULTS: High SATB2 expression was associated with a prolonged CSS in the full cohort (hazard ratio (HR) 1⁄4 0.61; 95% CI 0.41 – 0.92) and in colon cancer (HR 1⁄4 0.39; 95% CI 0.20 – 0.75), remaining significant in multivariable analysis of colon cancer (HR 1⁄4 0.49; 95% CI 0.25 – 0.96), with similar findings for OS. CONCLUSION: High SATB2 expression is an independent marker of good prognosis in colon cancer and may modulate sensitivity to chemotherapy and radiation. British Journal of Cancer (2012) 106, 931 – 938. doi:10.1038/bjc.2012.34 www.bjcancer.com Published online 14 February 2012 & 2012 Cancer Research UK
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
